MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Inventiva S.A. (NASDAQ: IVA)*
Organization & Developments: Inventiva
Parents
Inventiva S.A. (NASDAQ: IVA)*
Children
*Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
2019: French biotech Inventiva’s lead drug stumbles in systemic sclerosis study, ahead of NASH readout – Endpoints News
2020: Inventiva SA Starts U.S. IPO Rollout
2020: Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH
2024:Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
Jumps
Finance & Acquisition: Inventiva
Key People: Inventiva